Navigation Links
AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
Date:1/28/2010

LONDON, January 28 /PRNewswire-FirstCall/ -- Pharmaceutical group AstraZeneca announced it's Q4 and full-year results today with CEO David Brennan saying in a video interview on http://www.cantos.com that cost control and restructuring had helped deliver a revenue line above company expectations.

In the video Mr Brennan looks at the results and the drivers behind a 23% rise in core operating profit and, significantly, a 12% dividend increase. He discusses the rationale behind the "significant" R&D changes that the company is implementing as well as progress on the ongoing restructuring programme and where he sees future growth and opportunities coming from.

While he says the next five years will be challenging, the long-term future looks strong.

"We're entering a period of time where we are launching new products and we're excited about them, but it's going to take a few years for those products to get up to the revenue contribution that we need that will balance some of the patent expirations."

The interview and transcript are available now on http://www.cantos.com/company/astrazeneca.

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email

SOURCE AstraZeneca Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease
2. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
3. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
4. BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
5. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
6. AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
7. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
8. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
9. AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
10. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
11. Melior Enters Research Collaboration with AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015 Stent ... clots from vessels in the brain reduced disability ... by Tudor Jovin, MD, President of the Society ... "This is a giant step forward that ... treatment of stroke patients," said Jovin, who is ...
(Date:4/20/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and ... and commercializing proven cancer therapies in new orphan ... the 106th Annual Meeting of the American ... on the potential for its lead product candidate ...
(Date:4/20/2015)... 20, 2015 PMG Research, Inc ... clinical research site: PMG Research of Christie Clinic. Effective ... the clinical research department at Christie Clinic ... to a second region within the United States. This ... enhances PMG’s access to an additional 80,000 patients. For ...
(Date:4/20/2015)... FORT WORTH, Texas , April 20, 2015 /PRNewswire/ ... by orthopedic surgeons for healing bone injuries. The orthobiologics ... of growth opportunities for its stakeholders. The global orthobiologics ... analysis and forecast of revenue. The global orthobiologics market ... projected to reach $7,900.2 million by 2019, at a ...
Breaking Biology Technology:SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3
... Company now officially following an FDA 510(k) (Pre-Market Notification), Pathway for ... ... Human Appendicitis, CASTLE ROCK, Colo., Nov. 27 AspenBio Pharma,Inc. ... of novel drugs and diagnostics for animals and humans, has,received an ...
... Shamir,Optical Industry Ltd. (Nasdaq: SHMR ) ("Shamir"), a ... ophthalmic lens,market, today announced unaudited financial results for the ... ended September 30, 2007, revenues increased by 28.5%,to $30.9 ... of 2006.,Gross profit for the quarter increased by 25.3% ...
... Masimo receives approval from Ministry of Health, Labor and Welfare ... carbon ... monoxide levels in the blood, IRVINE, Calif., ... Motion and Low Perfusion pulse,oximetry, today announced approval of the ...
Cached Biology Technology:AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 2AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 4Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 2Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 3Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 4Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 5Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 6Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 7Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 8Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 9Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results 10Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 2Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 3Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 4
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3
... A study that relates global energy use to economic ... , finds strong correlations between these two measures both ... leads the study,s authors to infer that energy use ... increase in energy supply will be required to meet ...
... French . Scientists have discovered direct evidence of ... ammonites, distant relatives of squids, octopuses and cuttlefishes. The discovery ... 65.5 million years ago, at the end of the Cretaceous. ... fossils but until now, there has been no experimental evidence ...
... native perennials instead of corn in the Midwest,s rolling ... University research suggests. Federal mandates and market forces ... biologist Bruce Robertson says, but the environmental consequences of ... are a serious concern. Ethanol in America is ...
Cached Biology News:Study finds energy limits global economic growth 2Ammonites' last meal: New light on past marine food chains 2Ammonites' last meal: New light on past marine food chains 3Biofuel grasslands better for birds than ethanol staple corn, researchers find 2
... Each vial contains 200 g of ... receptor sequence (C-terminal amino acids 380-402; GLTPSAWEASSLRSSRHSGLSHF. ... an antigen for production of Cayman's EP1 ... can be used in conjunction with this ...
Anti-ZFP200 Family: Zinc Finger Peptide Sequence: CGKSFNHKTNLNKHER...
Complete cell culture media with cytokines...
Consists of 4 separate 100mM solutions (ATP,GTP,CTP and UTP pH 7.5) as sodium salts. 98% Pure by HPLC...
Biology Products: